MiNK Therapeutics (INKT) Earnings Date & Reports

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

INKT is expected to report earnings to fall 90.32% to -5 cents per share on May 07

MiNK Therapeutics INKT Stock Earnings Reports

Q1'25

Est.

$-0.06

Q4'24

Missed

by $0.54

Q3'24

Beat

by $0.03

Q2'24

Beat

by $0.03

Q1'24

Beat

by $0.04

The last earnings report on March 18 showed earnings per share of -62 cents, missing the estimate of -7 cents. With 2.70K shares outstanding, the current market capitalization sits at 30.07M.

View a ticker or compare two or three

Compare

INKT